Risk-reducing surgery for ovarian cancer: Outcomes in 300 surgeries suggest a low peritoneal primary risk

European Journal of Human Genetics

Volumn 17, Issue 11, 2009, Pages 1381-1385

  Evans, D Gareth R ^a   Clayton, Richard ^a   Donnai, Paul ^a   Shenton, Andrew ^a   Lalloo, Fiona ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENE MUTATION; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; OCCULT CANCER; OUTCOME ASSESSMENT; OVARY CANCER; PERITONEAL DISEASE; PRIORITY JOURNAL; RISK REDUCTION; SALPINGOOOPHORECTOMY;

FALLOPIAN TUBES; FEMALE; FOLLOW-UP STUDIES; GENES, BRCA1; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; MUTATION; OVARIAN NEOPLASMS; OVARIECTOMY; PERITONEAL NEOPLASMS; RISK MANAGEMENT;

EID: 70350367718     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2009.60     Document Type: Article

References (22)

1. Young RC, Walton LA, Ellenberg SS et al: Adjuvant therapy in stage I and stage II epithelial ovarian cancers. Results of two prospective randomised trials. N Engl J Med 1990; 322: 1021-1027.
2. Evans DGR: Risk estimation in ovarian cancer; in Lalloo F, Kerr B, Friedman J, Evans DGR (eds): Risk Assessment and Management in Cancer Genetics. Oxford University Press, Oxford, 2005, pp 73-82.
3. Chappius PO, Foulkes WD: Overview of the clinical genetics of ovarian cancer; in Morrison PJ, Hodgson SV, Haites NE (eds): Familial Breast and Ovarian Cancer: Genetics, Screening and Management. Cambridge University Press, Cambridge, 2002, pp 43-72.
4. Stratton JF, Pharoah P, Smith SK, Easton D, Ponder BA: A systematic review and meta-analysis of family history and risk associated with ovarian cancer. Br J Obstet Gynaecol 1998; 105: 493-499.
5. Risch HA, McLaughlin JR, Cole DE et al: Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: A kincohort study in Ontario, Canada. J Natl Cancer Inst 2006; 98: 1694-1706.
6. Thompson D, Easton DF: Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 94: 1358-1365.
7. Moller P, Hagen AI, Apold J et al: Genetic epidemiology of BRCA mutation - family history identifies less than 50% of mutation carriers. Eur J Cancer 2007; 43: 1713-1717.
8. Ford D, Easton DF, Stratton M et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-689.
9. Aarnio M, Sankila R, Pukkala E et al: Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999; 81 214-218.
10. Hogg R, Freidlander M: Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol 2004; 22: 1315-1327.
11. Hermsen BB, Olivier RI, Verheijen RH et al: No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer 2007; 96: 1335-1342.
12. Gaarenstroom KN, van der Hiel B, Tollenaar RA et al: Efficacy of screening women at high risk of hereditary ovarian cancer: Results of an 11-year cohort study. Int J Gynecol Cancer 2006; 16 (Suppl 1): 54-59.
13. Dorum A, Heimdal K, Lovslett K et al: Prospectively detected cancer in familial breast/ovarian cancer screening. Acta Obstet Gynecol Scand 1999; 78: 906-911.
14. Stirling D, Evans DG, Pichert G et al: Familial ovarian cancer screening: Current protocols are ineffective in detecting early stage ovarian malignancy. J Clin Oncol 2005; 23: 5588-5596.
15. Munkarah A, Chatterjee M, Tainsky MA: Update on ovarian cancer screening. Curr Opin Obstet Gynecol 2007; 19: 22-26.
16. Rebbeck TR, Kauff ND, Domchek SM: Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009; 101: 80-87.
17. Rebbeck TR, Lynch HT, Neuhausen SL et al: Prevention and observation of surgical end points study group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346: 1616-1621.
18. Kauff ND, Domchek SM, Friebel TM et al: Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: A multicenter, prospective study. J Clin Oncol 2008; 26: 1331-1337.
19. Kauff ND, Satagopan JM, Robson ME et al: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346: 1609-1615.
20. Piver MS, Jishi MF, Tsukada Y, Nava G: Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Family Ovarian Cancer Registry. Cancer 1993; 71: 2751-2755.
21. Evans DG, Gaarenstroom KN, Stirling D et al: Screening for familial ovarian cancer: Poor survival of BRCA1/2 related cancers. J Med Genet 2008 [E-pub ahead of print].
22. Powell CB, Kenley E, Chen LM et al: Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: Role of serial sectioning in the detection of occult malignancy. J Clin Oncol 2005; 23: 127-132.